Previous 10 | Next 10 |
Industry veteran and prominent diabetes clinical development expert to oversee Biomea’s progressing clinical development of novel covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes Steve Morris, M.D., will transition to the role of Chief Development Officer, continuing ...
2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...
2023-07-31 17:09:17 ET Biomea Fusion press release ( NASDAQ: BMEA ): Q2 GAAP EPS of -$0.70. cash, cash equivalents, restricted cash, and investments of $223.3 million, compared to $113.4 million as of December 31, 2022. For further details see: Biomea Fusion GAAP...
Reported additional positive clinical data at ADA 83 rd Scientific Sessions from the first two cohorts of patients with type 2 diabetes from ongoing Phase I/II study (COVALENT-111) evaluating BMF-219 as a novel, potentially disease-modifying treatment candidate for patients with type 2 diabet...
Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4 Dose Level 4 exposure correlates with initial activity seen in BMF-219’s pre-clinical studies Safety...
2023-07-16 01:39:20 ET Summary Biomea Fusion is a clinical-stage biotech company developing covalent small molecule inhibitors, with its lead asset BMF-219 showing promising initial phase 2 data for Type 2 diabetes. The company's core strategy is to leverage its proprietary FUSION Sys...
2023-07-14 17:29:54 ET Gainers: BridgeBio Pharma ( NASDAQ: BBIO ) +15% . Greenidge Generation ( GREE ) +5% . Conduent ( CNDT ) +3% . The RealReal ( REAL ) +3% . Quantum-Si ( QSI ) +3% . Losers: Ebix ...
ATLANTA, July 10, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Biomea Fusion, Inc. (“Biomea Fusion,” or the “Company”) (NASDAQ: BMEA) complied with federal securities laws. On June 23, 2023, the Company presented data for its type 2...
2023-06-26 13:37:01 ET Jefferies has downgraded Biomea Fusion ( NASDAQ: BMEA ) to hold following the company's presentation of data for its type 2 diabetes drug candidate BMF-219 at a meeting of the American Diabetes Association this past weekend. The investment bank said the da...
2023-06-26 06:51:33 ET Shares of Biomea Fusion ( NASDAQ: BMEA ) gained ~19% pre-market Monday as Wall Street reacted to the latest data from the company’s ongoing Phase 1/2 clinical study for lead asset BMF-219 in adults with uncontrolled type 2 diabetes. 12-week data...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information...